Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial

פריטים דומים

• Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial
  מאת: Danne, Thomas, et al.
  יצא לאור: (2020)
• The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3
  מאת: Yale, Jean-François, et al.
  יצא לאור: (2018)
• Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
  מאת: Steinstraesser, A, et al.
  יצא לאור: (2014)
• SUN-LB126 Real-World Safety and Effectiveness of Insulin Glargine 300 U/ML (Gla-300) in People With Type 2 Diabetes Who Fast During Ramadan
  מאת: Hassanein, Mohamed, et al.
  יצא לאור: (2020)
• A post‐hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla‐300) versus 100 U/mL (Gla‐100) over wider nocturnal windows in individuals with type 2 diabetes on a basal‐only insulin regimen
  מאת: Bolli, Geremia B., et al.
  יצא לאור: (2018)